BRIEF—Scancell in-licenses SNAPvax from Vaccitech

British immunotherapy specialist Scancell has in-licensed the SNAPvax technology from Vaccitech, enabling it to formulate and manufacture Modi-2.

Scancell is targeting a Phase I oncology trial for the candidate, the second to originate from its Moditope platform, in 2024.

The newly-licensed tech is designed to enable peptides to self-assemble with a powerful adjuvant, creating stronger T cell responses.

Chief executive Lindy Durrant said: “We are pleased to partner with Vaccitech to take the second candidate from our Moditope platform through GMP and subsequent clinical development.”

Scancell’s Modi-1 is already in Phase I testing.